(Content, formatting) |
|||
| Line 14: | Line 14: | ||
**Other | **Other | ||
==ADD/ADHD== | ==ADD/ADHD== | ||
| Line 42: | Line 29: | ||
*Citation: D.V. Poltavski, T. Petros, Effects of transdermal nicotine on attention in adult non-smokers with and without attentional deficits, Physiology & Behavior, Volume 87, Issue 3, 2006, Pages 614-624, ISSN 0031-9384, doi: 10.1016/j.physbeh.2005.12.011. | *Citation: D.V. Poltavski, T. Petros, Effects of transdermal nicotine on attention in adult non-smokers with and without attentional deficits, Physiology & Behavior, Volume 87, Issue 3, 2006, Pages 614-624, ISSN 0031-9384, doi: 10.1016/j.physbeh.2005.12.011. | ||
*Keywords: ADHD, Transdermal nicotine, CPT, WCST, Stroop, Attention, Memory | *Keywords: ADHD, Transdermal nicotine, CPT, WCST, Stroop, Attention, Memory | ||
==Addiction== | ==Addiction== | ||
| Line 54: | Line 43: | ||
*[https://sci-hub.se/10.1093/ntr/ntr137 PDF Version] | *[https://sci-hub.se/10.1093/ntr/ntr137 PDF Version] | ||
*Citation: Karl Fagerström, Ph.D., Determinants of Tobacco Use and Renaming the FTND to the Fagerström Test for Cigarette Dependence, Nicotine & Tobacco Research, Volume 14, Issue 1, January 2012, Pages 75–78, doi: 10.1093/ntr/ntr137 | *Citation: Karl Fagerström, Ph.D., Determinants of Tobacco Use and Renaming the FTND to the Fagerström Test for Cigarette Dependence, Nicotine & Tobacco Research, Volume 14, Issue 1, January 2012, Pages 75–78, doi: 10.1093/ntr/ntr137 | ||
==Alzheimer / Dementia / MCI== | ==Alzheimer / Dementia / MCI== | ||
| Line 108: | Line 99: | ||
*[https://sci-hub.st/10.1192/bjp.154.6.797 PDF Version] | *[https://sci-hub.st/10.1192/bjp.154.6.797 PDF Version] | ||
*Citation: Sahakian B, Jones G, Levy R, Gray J, Warburton D. The effects of nicotine on attention, information processing, and short-term memory in patients with dementia of the Alzheimer type. Br J Psychiatry. 1989 Jun;154:797-800. doi: 10.1192/bjp.154.6.797. PMID: 2597885. | *Citation: Sahakian B, Jones G, Levy R, Gray J, Warburton D. The effects of nicotine on attention, information processing, and short-term memory in patients with dementia of the Alzheimer type. Br J Psychiatry. 1989 Jun;154:797-800. doi: 10.1192/bjp.154.6.797. PMID: 2597885. | ||
==Aphthous ulcers== | ==Aphthous ulcers== | ||
| Line 115: | Line 108: | ||
*[https://sci-hub.st/10.5694/j.1326-5377.1991.tb121180.x PDF Version] | *[https://sci-hub.st/10.5694/j.1326-5377.1991.tb121180.x PDF Version] | ||
*Citation: Bittoun, R. (1991), Recurrent aphthous ulcers and nicotine. Medical Journal of Australia, 154: 471-472. https://doi.org/10.5694/j.1326-5377.1991.tb121180.x | *Citation: Bittoun, R. (1991), Recurrent aphthous ulcers and nicotine. Medical Journal of Australia, 154: 471-472. https://doi.org/10.5694/j.1326-5377.1991.tb121180.x | ||
==Arthritis== | ==Arthritis== | ||
| Line 127: | Line 122: | ||
*Acknowledgements: This research was supported by grants from the National Institutes of Health to FGZ (5R01DC015587), to RM (4R01-DC013200) and a pre-doctoral fellowship to CQP (UL1-TR000153). | *Acknowledgements: This research was supported by grants from the National Institutes of Health to FGZ (5R01DC015587), to RM (4R01-DC013200) and a pre-doctoral fellowship to CQP (UL1-TR000153). | ||
*Keywords: Acetylcholinergic systems; Auditory processing; Nicotine; Selective attention; Spectral ripple discrimination; Temporal gap detection; Tone in noise detection. | *Keywords: Acetylcholinergic systems; Auditory processing; Nicotine; Selective attention; Spectral ripple discrimination; Temporal gap detection; Tone in noise detection. | ||
==Autism== | ==Autism== | ||
| Line 137: | Line 134: | ||
*Acknowledgements: This work was supported by Autism Speaks grant #9699 (ASL), National Institutes of Health grants R01DA14241 and R01MH077681 (MRP), R25MH071584, T32MH019961, and T32MH14276 (ASL), and the Child Study Center Associates and the AACAP Pilot Award for General Psychiatry Residents (GIvS). | *Acknowledgements: This work was supported by Autism Speaks grant #9699 (ASL), National Institutes of Health grants R01DA14241 and R01MH077681 (MRP), R25MH071584, T32MH019961, and T32MH14276 (ASL), and the Child Study Center Associates and the AACAP Pilot Award for General Psychiatry Residents (GIvS). | ||
*Keywords: Nicotine; nicotinic acetylcholine receptor; autism spectrum disorder; aggression; irritability; adult; sleep | *Keywords: Nicotine; nicotinic acetylcholine receptor; autism spectrum disorder; aggression; irritability; adult; sleep | ||
==Behcet's disease== | ==Behcet's disease== | ||
| Line 150: | Line 149: | ||
*[https://sci-hub.st/10.1056/NEJM200012143432418 PDF Version] (Note: Need to scroll down to the correct section) | *[https://sci-hub.st/10.1056/NEJM200012143432418 PDF Version] (Note: Need to scroll down to the correct section) | ||
*Citation: Philippe Scheid, M.D., Abraham Bohadana, M.D., Yves Martinet, M.D., Ph.D., Université Henri Poincaré, 54500 Nancy-Vandoeuvre, France, December 14, 2000, N Engl J Med 2000; 343:1816-1817, DOI: 10.1056/NEJM200012143432418 | *Citation: Philippe Scheid, M.D., Abraham Bohadana, M.D., Yves Martinet, M.D., Ph.D., Université Henri Poincaré, 54500 Nancy-Vandoeuvre, France, December 14, 2000, N Engl J Med 2000; 343:1816-1817, DOI: 10.1056/NEJM200012143432418 | ||
==Brain Injury / Disease== | ==Brain Injury / Disease== | ||
| Line 159: | Line 160: | ||
*Acknowledgements: This work was supported by grants from the National Institutes of Health (NS42196 to J.R.P. and NS39828 to S.W.S.) and the Kentucky Tobacco Research and Development Center. We acknowledge the technical assistance of Melissa Yingling and Khaled Tanwir. | *Acknowledgements: This work was supported by grants from the National Institutes of Health (NS42196 to J.R.P. and NS39828 to S.W.S.) and the Kentucky Tobacco Research and Development Center. We acknowledge the technical assistance of Melissa Yingling and Khaled Tanwir. | ||
*KEYWORDS: nicotine; neurodegeneration; neuroprotection | *KEYWORDS: nicotine; neurodegeneration; neuroprotection | ||
==Cancer / Cancer Treatments== | ==Cancer / Cancer Treatments== | ||
| Line 178: | Line 181: | ||
*Acknowledgements: This work was supported by the Italian Ministry of Instruction, University and Research. | *Acknowledgements: This work was supported by the Italian Ministry of Instruction, University and Research. | ||
*Keywords: nAChR; Dideoxycytidine; Oxaliplatin; Antiviral; Anticancer, pain, chemotherapy, nicotine, neuropathy | *Keywords: nAChR; Dideoxycytidine; Oxaliplatin; Antiviral; Anticancer, pain, chemotherapy, nicotine, neuropathy | ||
| Line 188: | Line 192: | ||
*Acknowledgement: The study was supported by NIH grant R01DA031006 awarded to David Gilbert. | *Acknowledgement: The study was supported by NIH grant R01DA031006 awarded to David Gilbert. | ||
*Keywords: Cannabis; Marijuana; Negative affect; Nicotine; Smoking; THC; Testing effect; Withdrawal symptoms. | *Keywords: Cannabis; Marijuana; Negative affect; Nicotine; Smoking; THC; Testing effect; Withdrawal symptoms. | ||
| Line 226: | Line 231: | ||
*Citation: Warburton DM. Nicotine as a cognitive enhancer. Prog Neuropsychopharmacol Biol Psychiatry. 1992 Mar;16(2):181-91. doi: 10.1016/0278-5846(92)90069-q. PMID: 1579636. | *Citation: Warburton DM. Nicotine as a cognitive enhancer. Prog Neuropsychopharmacol Biol Psychiatry. 1992 Mar;16(2):181-91. doi: 10.1016/0278-5846(92)90069-q. PMID: 1579636. | ||
*Keywords: acetylcholine, Alzheimer's Disease, attention, cholinergic, memory, nicotine, scopolamine. | *Keywords: acetylcholine, Alzheimer's Disease, attention, cholinergic, memory, nicotine, scopolamine. | ||
==Digestive Tract / Bowel== | ==Digestive Tract / Bowel== | ||
| Line 264: | Line 271: | ||
*Citation: Jarvik ME. Beneficial effects of nicotine. Br J Addict. 1991 May;86(5):571-5. doi: 10.1111/j.1360-0443.1991.tb01810.x. PMID: 1859921. | *Citation: Jarvik ME. Beneficial effects of nicotine. Br J Addict. 1991 May;86(5):571-5. doi: 10.1111/j.1360-0443.1991.tb01810.x. PMID: 1859921. | ||
*Acknowledgement: Supported by U. C. Tobacco-related Disease program, grant # RT87 and a grant from the John D. and Catherine T. MacArthur Foundation. | *Acknowledgement: Supported by U. C. Tobacco-related Disease program, grant # RT87 and a grant from the John D. and Catherine T. MacArthur Foundation. | ||
==Downs Syndrome== | ==Downs Syndrome== | ||
| Line 272: | Line 281: | ||
*Seidl R, Tiefenthaler M, Hauser E, Lubec G. Effects of transdermal nicotine on cognitive performance in Down's syndrome. Lancet. 2000 Oct 21;356(9239):1409-10. doi: 10.1016/S0140-6736(00)02848-8. PMID: 11052587. | *Seidl R, Tiefenthaler M, Hauser E, Lubec G. Effects of transdermal nicotine on cognitive performance in Down's syndrome. Lancet. 2000 Oct 21;356(9239):1409-10. doi: 10.1016/S0140-6736(00)02848-8. PMID: 11052587. | ||
*Acknowledgements: We thank Pharmacia-Upjohn, Uppsala, Sweden, for providing transdermal nicotine patches. This study was supported by the Red Bull Company, Salzburg. | *Acknowledgements: We thank Pharmacia-Upjohn, Uppsala, Sweden, for providing transdermal nicotine patches. This study was supported by the Red Bull Company, Salzburg. | ||
==Endurance / Exercise / Athletic Performance== | ==Endurance / Exercise / Athletic Performance== | ||
| Line 279: | Line 290: | ||
*[https://physoc.onlinelibrary.wiley.com/doi/pdf/10.1113/expphysiol.2006.033373 PDF Version] | *[https://physoc.onlinelibrary.wiley.com/doi/pdf/10.1113/expphysiol.2006.033373 PDF Version] | ||
*Mündel, T. and Jones, D.A. (2006), Effect of transdermal nicotine administration on exercise endurance in men. Experimental Physiology, 91: 705-713. doi: 10.1113/expphysiol.2006.033373 | *Mündel, T. and Jones, D.A. (2006), Effect of transdermal nicotine administration on exercise endurance in men. Experimental Physiology, 91: 705-713. doi: 10.1113/expphysiol.2006.033373 | ||
==HIV/AIDS== | ==HIV/AIDS== | ||
==Mental Health - Anxiety== | ==Mental Health - Anxiety== | ||
==Mental Health - Behavior Issues== | ==Mental Health - Behavior Issues== | ||
| Line 299: | Line 318: | ||
*Acknowledgements: This work was supported by Autism Speaks grant #9699 (ASL), National Institutes of Health grants R01DA14241 and R01MH077681 (MRP), R25MH071584, T32MH019961, and T32MH14276 (ASL), and the Child Study Center Associates and the AACAP Pilot Award for General Psychiatry Residents (GIvS). | *Acknowledgements: This work was supported by Autism Speaks grant #9699 (ASL), National Institutes of Health grants R01DA14241 and R01MH077681 (MRP), R25MH071584, T32MH019961, and T32MH14276 (ASL), and the Child Study Center Associates and the AACAP Pilot Award for General Psychiatry Residents (GIvS). | ||
*Keywords: Nicotine; nicotinic acetylcholine receptor; autism spectrum disorder; aggression; irritability; adult; sleep | *Keywords: Nicotine; nicotinic acetylcholine receptor; autism spectrum disorder; aggression; irritability; adult; sleep | ||
==Mental Health - Depression== | ==Mental Health - Depression== | ||
| Line 344: | Line 365: | ||
*Citation: Jarvik ME. Beneficial effects of nicotine. Br J Addict. 1991 May;86(5):571-5. doi: 10.1111/j.1360-0443.1991.tb01810.x. PMID: 1859921. | *Citation: Jarvik ME. Beneficial effects of nicotine. Br J Addict. 1991 May;86(5):571-5. doi: 10.1111/j.1360-0443.1991.tb01810.x. PMID: 1859921. | ||
*Acknowledgement: Supported by U. C. Tobacco-related Disease program, grant # RT87 and a grant from the John D. and Catherine T. MacArthur Foundation. | *Acknowledgement: Supported by U. C. Tobacco-related Disease program, grant # RT87 and a grant from the John D. and Catherine T. MacArthur Foundation. | ||
==Mental Health - Schizophrenia== | ==Mental Health - Schizophrenia== | ||
| Line 357: | Line 380: | ||
*[https://sci-hub.st/10.1016/j.mehy.2009.02.017 PDF Version] | *[https://sci-hub.st/10.1016/j.mehy.2009.02.017 PDF Version] | ||
*Citation: Conway JL. Exogenous nicotine normalises sensory gating in schizophrenia; therapeutic implications. Med Hypotheses. 2009 Aug;73(2):259-62. doi: 10.1016/j.mehy.2009.02.017. Epub 2009 Mar 27. PMID: 19328631. | *Citation: Conway JL. Exogenous nicotine normalises sensory gating in schizophrenia; therapeutic implications. Med Hypotheses. 2009 Aug;73(2):259-62. doi: 10.1016/j.mehy.2009.02.017. Epub 2009 Mar 27. PMID: 19328631. | ||
==Movement Disorders (not diagnosis specific)== | ==Movement Disorders (not diagnosis specific)== | ||
| Line 366: | Line 391: | ||
*Citation: Quik M, Zhang D, Perez XA, Bordia T. Role for the nicotinic cholinergic system in movement disorders; therapeutic implications. Pharmacol Ther. 2014 Oct;144(1):50-9. doi: 10.1016/j.pharmthera.2014.05.004. Epub 2014 May 14. PMID: 24836728; PMCID: PMC4149916. | *Citation: Quik M, Zhang D, Perez XA, Bordia T. Role for the nicotinic cholinergic system in movement disorders; therapeutic implications. Pharmacol Ther. 2014 Oct;144(1):50-9. doi: 10.1016/j.pharmthera.2014.05.004. Epub 2014 May 14. PMID: 24836728; PMCID: PMC4149916. | ||
*Acknowledgements: This work was supported by grants NS59910 and NS 65851 from the National Institutes of Health. | *Acknowledgements: This work was supported by grants NS59910 and NS 65851 from the National Institutes of Health. | ||
| Line 390: | Line 416: | ||
*[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3659034/pdf/icns_10_4_20.pdf PDF Version] | *[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3659034/pdf/icns_10_4_20.pdf PDF Version] | ||
*Citation: Naddafi F, Reza Haidari M, Azizi G, Sedaghat R, Mirshafiey A. Novel therapeutic approach by nicotine in experimental model of multiple sclerosis. Innov Clin Neurosci. 2013 Apr;10(4):20-5. PMID: 23696955; PMCID: PMC3659034. | *Citation: Naddafi F, Reza Haidari M, Azizi G, Sedaghat R, Mirshafiey A. Novel therapeutic approach by nicotine in experimental model of multiple sclerosis. Innov Clin Neurosci. 2013 Apr;10(4):20-5. PMID: 23696955; PMCID: PMC3659034. | ||
==OCD (Obsessive Compulsive Disorder)== | ==OCD (Obsessive Compulsive Disorder)== | ||
| Line 397: | Line 425: | ||
*[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7528475/pdf/12991_2020_Article_309.pdf PDF Version] | *[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7528475/pdf/12991_2020_Article_309.pdf PDF Version] | ||
*Citation: Piacentino D, Maraone A, Roselli V, Berardelli I, Biondi M, Kotzalidis GD, Pasquini M. Efficacy of nicotine administration on obsessions and compulsions in OCD: a systematic review. Ann Gen Psychiatry. 2020 Sep 30;19:57. doi: 10.1186/s12991-020-00309-z. PMID: 33014119; PMCID: PMC7528475. | *Citation: Piacentino D, Maraone A, Roselli V, Berardelli I, Biondi M, Kotzalidis GD, Pasquini M. Efficacy of nicotine administration on obsessions and compulsions in OCD: a systematic review. Ann Gen Psychiatry. 2020 Sep 30;19:57. doi: 10.1186/s12991-020-00309-z. PMID: 33014119; PMCID: PMC7528475. | ||
==Oral / Jaw== | ==Oral / Jaw== | ||
| Line 406: | Line 436: | ||
*Citation: Landim FS, Laureano Filho JR, Nascimento J, do Egito Vasconcelos BC. Effectiveness of nicotine patch for the control of pain, oedema, and trismus following third molar surgery: a randomized clinical trial. Int J Oral Maxillofac Surg. 2020 Nov;49(11):1508-1517. doi: 10.1016/j.ijom.2019.08.013. Epub 2020 May 4. PMID: 32381373. | *Citation: Landim FS, Laureano Filho JR, Nascimento J, do Egito Vasconcelos BC. Effectiveness of nicotine patch for the control of pain, oedema, and trismus following third molar surgery: a randomized clinical trial. Int J Oral Maxillofac Surg. 2020 Nov;49(11):1508-1517. doi: 10.1016/j.ijom.2019.08.013. Epub 2020 May 4. PMID: 32381373. | ||
*Acknowledgements: Funding - CAPES, Ministry of Education, Brazil | *Acknowledgements: Funding - CAPES, Ministry of Education, Brazil | ||
==Pain / Analgesic== | ==Pain / Analgesic== | ||
| Line 436: | Line 468: | ||
*[https://sci-hub.se/10.1213/ane.0b013e31816f2616# PDF Version] | *[https://sci-hub.se/10.1213/ane.0b013e31816f2616# PDF Version] | ||
*Citation: Habib, Ashraf S., MBBCh, MSc, FRCA*; White, William D., MPH*; El Gasim, Magdi A., MD*; Saleh, Gamal, MD*; Polascik, Thomas J., MD†; Moul, Judd W., MD†; Gan, Tong J., MB, FRCA* Transdermal Nicotine for Analgesia After Radical Retropubic Prostatectomy, Anesthesia & Analgesia: September 2008 - Volume 107 - Issue 3 - p 999-1004 doi: 10.1213/ane.0b013e31816f2616 | *Citation: Habib, Ashraf S., MBBCh, MSc, FRCA*; White, William D., MPH*; El Gasim, Magdi A., MD*; Saleh, Gamal, MD*; Polascik, Thomas J., MD†; Moul, Judd W., MD†; Gan, Tong J., MB, FRCA* Transdermal Nicotine for Analgesia After Radical Retropubic Prostatectomy, Anesthesia & Analgesia: September 2008 - Volume 107 - Issue 3 - p 999-1004 doi: 10.1213/ane.0b013e31816f2616 | ||
==Parkinson Disease== | ==Parkinson Disease== | ||
| Line 464: | Line 498: | ||
*Citation: Jarvik ME. Beneficial effects of nicotine. Br J Addict. 1991 May;86(5):571-5. doi: 10.1111/j.1360-0443.1991.tb01810.x. PMID: 1859921. | *Citation: Jarvik ME. Beneficial effects of nicotine. Br J Addict. 1991 May;86(5):571-5. doi: 10.1111/j.1360-0443.1991.tb01810.x. PMID: 1859921. | ||
*Acknowledgement: Supported by U. C. Tobacco-related Disease program, grant # RT87 and a grant from the John D. and Catherine T. MacArthur Foundation. | *Acknowledgement: Supported by U. C. Tobacco-related Disease program, grant # RT87 and a grant from the John D. and Catherine T. MacArthur Foundation. | ||
==Psoriasis== | ==Psoriasis== | ||
| Line 471: | Line 507: | ||
*[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3325452/pdf/0580404.pdf PDF Version] | *[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3325452/pdf/0580404.pdf PDF Version] | ||
*Citation: Staples J, Klein D. Can nicotine use alleviate symptoms of psoriasis? Can Fam Physician. 2012 Apr;58(4):404-8. PMID: 22611606; PMCID: PMC3325452. | *Citation: Staples J, Klein D. Can nicotine use alleviate symptoms of psoriasis? Can Fam Physician. 2012 Apr;58(4):404-8. PMID: 22611606; PMCID: PMC3325452. | ||
| Line 490: | Line 527: | ||
*[https://sci-hub.st/10.1111/j.1346-8138.1995.tb03904.x PDF Version] | *[https://sci-hub.st/10.1111/j.1346-8138.1995.tb03904.x PDF Version] | ||
*Citation: Kanekura T, Kanzaki T. Successful treatment of pyoderma gangrenosum with nicotine chewing gum. J Dermatol. 1995 Sep;22(9):704-5. doi: 10.1111/j.1346-8138.1995.tb03904.x. PMID: 8537562. | *Citation: Kanekura T, Kanzaki T. Successful treatment of pyoderma gangrenosum with nicotine chewing gum. J Dermatol. 1995 Sep;22(9):704-5. doi: 10.1111/j.1346-8138.1995.tb03904.x. PMID: 8537562. | ||
==Sarcoidosis== | ==Sarcoidosis== | ||
| Line 498: | Line 537: | ||
*Citation: Mark W. Julian, MS; Guohong Shao, MD; Larry S. Schlesinger, MD; Qin Huang, MD; David G. Cosmar, BA; Nitin Y. Bhatt, MD; Daniel A. Culver, MD, FCCP; Robert P. Baughman, MD, FCCP; Karen L. Wood, MD, FCCP; and Elliott D. Crouser, MD - ORIGINAL RESEARCH DIFFUSE LUNG DISEASE| VOLUME 143, ISSUE 2, P461-470, FEBRUARY 01, 2013, DOI 10.1378/chest.12-0383 | *Citation: Mark W. Julian, MS; Guohong Shao, MD; Larry S. Schlesinger, MD; Qin Huang, MD; David G. Cosmar, BA; Nitin Y. Bhatt, MD; Daniel A. Culver, MD, FCCP; Robert P. Baughman, MD, FCCP; Karen L. Wood, MD, FCCP; and Elliott D. Crouser, MD - ORIGINAL RESEARCH DIFFUSE LUNG DISEASE| VOLUME 143, ISSUE 2, P461-470, FEBRUARY 01, 2013, DOI 10.1378/chest.12-0383 | ||
*Acknowledgements: This work was supported by the American Thoracic Society and the Foundation for Sarcoidosis Research. © 2013 American College of Chest Physicians | *Acknowledgements: This work was supported by the American Thoracic Society and the Foundation for Sarcoidosis Research. © 2013 American College of Chest Physicians | ||
==Seizures / Epilepsy== | ==Seizures / Epilepsy== | ||
| Line 513: | Line 554: | ||
*Citation: Willoughby, J.O., Pope, K.J. and Eaton, V. (2003), Nicotine as an Antiepileptic Agent in ADNFLE: An N‐of‐One Study. Epilepsia, 44: 1238-1240. doi: 10.1046/j.1528-1157.2003.58102.x-i1 | *Citation: Willoughby, J.O., Pope, K.J. and Eaton, V. (2003), Nicotine as an Antiepileptic Agent in ADNFLE: An N‐of‐One Study. Epilepsia, 44: 1238-1240. doi: 10.1046/j.1528-1157.2003.58102.x-i1 | ||
*Acknowledgments: The Pharmacy Department undertook randomization and allocation of the trial phase. Nicotine patches and matching placebo patches were provided through SmithKlineBeecham Consumer Healthcare Australia. The patient was cooperatively conscientious in her documentation of seizures. Dr. Stephen Johnson provided helpful comments on nicotinic receptor pharmacology. | *Acknowledgments: The Pharmacy Department undertook randomization and allocation of the trial phase. Nicotine patches and matching placebo patches were provided through SmithKlineBeecham Consumer Healthcare Australia. The patient was cooperatively conscientious in her documentation of seizures. Dr. Stephen Johnson provided helpful comments on nicotinic receptor pharmacology. | ||
== Sleep Apnea== | == Sleep Apnea== | ||
| Line 521: | Line 564: | ||
*Citation: Jarvik ME. Beneficial effects of nicotine. Br J Addict. 1991 May;86(5):571-5. doi: 10.1111/j.1360-0443.1991.tb01810.x. PMID: 1859921. | *Citation: Jarvik ME. Beneficial effects of nicotine. Br J Addict. 1991 May;86(5):571-5. doi: 10.1111/j.1360-0443.1991.tb01810.x. PMID: 1859921. | ||
*Acknowledgement: Supported by U. C. Tobacco-related Disease program, grant # RT87 and a grant from the John D. and Catherine T. MacArthur Foundation. | *Acknowledgement: Supported by U. C. Tobacco-related Disease program, grant # RT87 and a grant from the John D. and Catherine T. MacArthur Foundation. | ||
==Spinal Cord Injury== | ==Spinal Cord Injury== | ||
| Line 532: | Line 577: | ||
*Acknowledgements: This work was supported in part by the Philip Morris External Research Program and the Kentucky Science and Engineering Foundation. | *Acknowledgements: This work was supported in part by the Philip Morris External Research Program and the Kentucky Science and Engineering Foundation. | ||
*Key words: spinal cord injury; nicotine; neuronal nicotinic receptors; oxidative stress; inflammatory responses; nitric oxide synthase | *Key words: spinal cord injury; nicotine; neuronal nicotinic receptors; oxidative stress; inflammatory responses; nitric oxide synthase | ||
==Tourette Syndrome== | ==Tourette Syndrome== | ||
===2001 [https://pubmed.ncbi.nlm.nih.gov/11681767/ Transdermal nicotine and haloperidol in Tourette's disorder: a double-blind placebo-controlled study]=== | ===2001 [https://pubmed.ncbi.nlm.nih.gov/11681767/ Transdermal nicotine and haloperidol in Tourette's disorder: a double-blind placebo-controlled study]=== | ||
*[[Abbreviations|'''Transdermal nicotine (TNP)''']] was superior to placebo in reducing behavioral symptoms when patients were receiving an optimal dose of haloperidol, when the dose of haloperidol was reduced by 50%, and when the patch had been discontinued for 2 weeks. These findings confirm earlier open-label findings and suggest that combining nicotinic receptor modulation and neuroleptics could be a therapeutic option for the treatment of Tourette's disorder | *[[Abbreviations|'''Transdermal nicotine (TNP)''']] was superior to placebo in reducing behavioral symptoms when patients were receiving an optimal dose of haloperidol, when the dose of haloperidol was reduced by 50%, and when the patch had been discontinued for 2 weeks. These findings confirm earlier open-label findings and suggest that combining nicotinic receptor modulation and neuroleptics could be a therapeutic option for the treatment of Tourette's disorder | ||
*[https://www.researchgate.net/profile/Paul_Sanberg/publication/11670769_Transdermal_Nicotine_and_Haloperidol_in_Tourette's_Disorder/links/5be32624299bf1124fc2d86a/Transdermal-Nicotine-and-Haloperidol-in-Tourettes-Disorder.pdf PDF Version] | *[https://www.researchgate.net/profile/Paul_Sanberg/publication/11670769_Transdermal_Nicotine_and_Haloperidol_in_Tourette's_Disorder/links/5be32624299bf1124fc2d86a/Transdermal-Nicotine-and-Haloperidol-in-Tourettes-Disorder.pdf PDF Version] | ||
*Citation: Silver AA, Shytle RD, Philipp MK, Wilkinson BJ, McConville B, Sanberg PR. Transdermal nicotine and haloperidol in Tourette's disorder: a double-blind placebo-controlled study. J Clin Psychiatry. 2001 Sep;62(9):707-14. doi: 10.4088/jcp.v62n0908. PMID: 11681767. | *Citation: Silver AA, Shytle RD, Philipp MK, Wilkinson BJ, McConville B, Sanberg PR. Transdermal nicotine and haloperidol in Tourette's disorder: a double-blind placebo-controlled study. J Clin Psychiatry. 2001 Sep;62(9):707-14. doi: 10.4088/jcp.v62n0908. PMID: 11681767. | ||
| Line 577: | Line 624: | ||
*Citation: D.E. Moss, Patricia Z. Manderscheid, S.P. Montgomery, Andrew B. Norman, Paul R. Sanberg, Nicotine and cannabinoids as adjuncts to neuroleptics in the treatment of tourette syndrome and other motor disorders, Life Sciences, Volume 44, Issue 21, 1989, Pages 1521-1525, ISSN 0024-3205, doi.org/10.1016/0024-3205(89)90444-X. | *Citation: D.E. Moss, Patricia Z. Manderscheid, S.P. Montgomery, Andrew B. Norman, Paul R. Sanberg, Nicotine and cannabinoids as adjuncts to neuroleptics in the treatment of tourette syndrome and other motor disorders, Life Sciences, Volume 44, Issue 21, 1989, Pages 1521-1525, ISSN 0024-3205, doi.org/10.1016/0024-3205(89)90444-X. | ||
*Acknowledgements: Supported in part by NIMH (RR 08012) and NIDA. Levonantradol and fluphenazine HCL were generous gifts from Pfizer Pharmaceuticals (Groton, Conn.) and E.R. Squibb and Sons (Princeton, N.J.), respectively. | *Acknowledgements: Supported in part by NIMH (RR 08012) and NIDA. Levonantradol and fluphenazine HCL were generous gifts from Pfizer Pharmaceuticals (Groton, Conn.) and E.R. Squibb and Sons (Princeton, N.J.), respectively. | ||
==Weight Loss / Appetite Control / Metabolism / Obesity== | ==Weight Loss / Appetite Control / Metabolism / Obesity== | ||
| Line 585: | Line 634: | ||
*Citation: Jarvik ME. Beneficial effects of nicotine. Br J Addict. 1991 May;86(5):571-5. doi: 10.1111/j.1360-0443.1991.tb01810.x. PMID: 1859921. | *Citation: Jarvik ME. Beneficial effects of nicotine. Br J Addict. 1991 May;86(5):571-5. doi: 10.1111/j.1360-0443.1991.tb01810.x. PMID: 1859921. | ||
*Acknowledgement: Supported by U. C. Tobacco-related Disease program, grant # RT87 and a grant from the John D. and Catherine T. MacArthur Foundation. | *Acknowledgement: Supported by U. C. Tobacco-related Disease program, grant # RT87 and a grant from the John D. and Catherine T. MacArthur Foundation. | ||
==Suggested studies to add to this page== | |||
===2017 [https://www.ncbi.nlm.nih.gov/pubmed/27940486 Moist smokeless tobacco (Snus) use and risk of Parkinson's disease]=== | |||
*Smoke-free nicotine appears to reduce the risk of Parkinson’s disease by 60%. | |||
===[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC526783/ Nicotine as Therapy]=== | |||
===Dr. Newhouse [http://mindstudy.org/news Mind Study]=== | |||
===[https://journals.sagepub.com/doi/abs/10.1177/0883073820974851?journalCode=jcna Nicotine: A Targeted Therapy for Epilepsy Due to nAChR Gene Variants]=== | |||
===[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7704168/ Does Nicotine Prevent Cytokine Storms in COVID-19?]=== | |||
===[https://pubmed.ncbi.nlm.nih.gov/32595653/ Cytokine Release Syndrome (CRS) and Nicotine in COVID-19 Patients: Trying to Calm the Storm]=== | |||
===[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3592351/ Targeting the “Cytokine Storm” for Therapeutic Benefit]=== | |||
===Fluharty et al (2016). [https://pubmed.ncbi.nlm.nih.gov/27199385/ The association of cigarette smoking with depression and anxiety: a systematic review.] Nicotine & Tobacco Research=== | |||
*“The literature on the prospective association between smoking and depression and anxiety is inconsistent in terms of the direction of association most strongly supported. This suggests the need for future studies that employ different methodologies, such as Mendelian randomization. . . . Two studies that have used [Mendelian randomization] have found no evidence to support a causal association between smoking and depression and anxiety, while another found evidence to suggest that smoking was associated with lower odds of depression during pregnancy.” | |||
===2010 [https://pubmed.ncbi.nlm.nih.gov/20414766/ Meta-analysis of the acute effects of nicotine and smoking on human performance] and 2012 [https://n.neurology.org/content/78/2/91.short Nicotine treatment of mild cognitive impairment A 6-month double-blind pilot clinical trial]=== | |||
*Clinical studies suggest some cognitive improvements as a result of nicotine. | |||
==More Information== | ==More Information== | ||
===[[Nicotine_Studies|'''List of researchers''']] studying nicotine / tobacco harm reduction=== | ===[[Nicotine_Studies|'''List of researchers''']] studying nicotine / tobacco harm reduction=== | ||
[[Category:Studies, Surveys, and Papers]] | [[Category:Studies, Surveys, and Papers]] | ||
edits